Bioretec in brief

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has unique expertise combining materials engineering and biochemistry in active implants that promote bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are sold worldwide in approximately 40 countries.

Bioretec’s new RemeOs™ product family is based on a next generation of strong bioresorbable materials, magnesium alloy and hybrid composite. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing.

Established in 2003 and headquartered in Tampere, Finland, Bioretec employed 37 professionals at the end of December 2023. In addition, the company’s operations are supported by the Scientific Advisory Board consisting of distinguished international surgeons and by a Regulatory Advisor. Bioretec’s share is listed on the Nasdaq First North Growth Market Finland marketplace under the trading code BRETEC.

Latest

• Financial statement bulletin and financial statement 2024 have been published to Reports and presentations (14.2.2025)

• Business review January – September 2024 and 2024-Q3 business review presentation have been published to Reports and presentations  (14.11.2024)

• Half-year report January-June 2024 has been published to Reports and presentations (15.8.2024)

• Investor presentation (4.10.2024)

• Business review January–March 2024 been published to Reports and presentations (16.5.2024)

• Financial statements and annual report 2023 has been published to Reports and presentations (15.3.2024)

• Danske Bank – Small Cap Day (14.3.2024)
  Material published in Reports and presentations

• Financial statement bulletin 2023 has been published to Reports and presentations(16.2.2024)